Halcinonide Topical Dosage

Medically reviewed by Drugs.com. Last updated on Jul 24, 2023.

Usual Adult Dose for Dermatitis

Apply a thin film to affected area two to three times a day

Comments:

• Use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated, if an infection develops.

Use:

• Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

Usual Adult Dose for Eczema

Apply a thin film to affected area two to three times a day

Comments:

• Use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated, if an infection develops.

Use:

• Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

Usual Adult Dose for Psoriasis

Apply a thin film to affected area two to three times a day

Comments:

• Use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated, if an infection develops.

Use:

• Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

Usual Pediatric Dose for Dermatitis

Apply a thin film to affected area two to three times a day

Comments:

• Use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated, if an infection develops.

Use:

• Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

Usual Pediatric Dose for Eczema

Apply a thin film to affected area two to three times a day

Comments:

• Use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated, if an infection develops.

Use:

• Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

Usual Pediatric Dose for Psoriasis

Apply a thin film to affected area two to three times a day

Comments:

• Use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated, if an infection develops.

Use:

• Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This topical drug is not for ophthalmic, oral, or intravaginal use.
• The treated area should not be bandaged, covered, or wrapped, as to be occlusive, unless directed by a healthcare provider.
• Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area.

Occlusive dressing technique:

• Apply a thin film to the lesion, cover with a pliable nonporous film, and seal the edges.
• If necessary, more moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by wetting the affected area with water immediately prior to applying the topical drug.
• The frequency of changing dressings is determined on an individual basis.
• A convenient option would be to apply the topical drug under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion).
• If the 12-hour occlusion frequency is used, additional drug should be applied, without occlusion, during the day.
• Reapplication is necessary at each dressing change.

Storage requirement:
Store at room temperature; avoid excessive heat (104F/ 40 C)

Monitoring:

• Endocrine: HPA-axis suppression (Urinary free-cortisol test, ACTH-stimulation test)

Patient advice:

• Patients should report any signs of local adverse reactions, especially those that develop under occlusive dressings.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer